Cingulate (CINGW) Stock Analysis
NASDAQHealthcareBiotechnology
What Cingulate does
Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.
Key metrics
ETFs linked to CINGW
Broad-market and Healthcare sector ETFs an investor holding Cingulate is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how CINGW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze CINGW in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Cingulate?
- Cingulate trades under the ticker CINGW on NASDAQ.
- Which exchange is CINGW listed on?
- CINGW is listed on NASDAQ.
- What sector does Cingulate operate in?
- Cingulate is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze CINGW in a portfolio?
- PortView shows CINGW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.